EcoDrugPlus

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3b

Ensembl ID : ENSLCAG00010021750
Gene Symbol: P2RX3B
1 Cross references
195 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSLCAG00010002613
Gene Symbol: P2RY1
4 Cross references
190 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSLCAG00010000843
Gene Symbol: P2RY2
4 Cross references
197 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSLCAG00010017639
Gene Symbol: P2RY4
4 Cross references
165 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSLCAG00010000809
Gene Symbol: P2RY6
4 Cross references
182 Possible Orthologues:

Receptor (Tnfrsf)-Interacting Serine-Threonine Kinase 1, Like

Ensembl ID : ENSLCAG00010009640
Gene Symbol: RIPK1L
4 Cross references
197 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSLCAG00010028071
Gene Symbol: LOC108887097
4 Cross references
191 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSLCAG00010021169
Gene Symbol: RAMP1
4 Cross references
184 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-4

Ensembl ID : ENSLCAG00010021427
Gene Symbol: LOC108873032
4 Cross references
230 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSLCAG00010010545
Gene Symbol: RPTOR
1 Cross references
213 Possible Orthologues:

Renin

Ensembl ID : ENSLCAG00010018469
Gene Symbol: REN
4 Cross references
219 Possible Orthologues:

Ret Proto-Oncogene Receptor Tyrosine Kinase

Ensembl ID : ENSLCAG00010008233
Gene Symbol: LOC108886252
4 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).